{"id":"NCT02358031","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)","officialTitle":"A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-19","primaryCompletion":"2019-02-25","completion":"2023-07-19","firstPosted":"2015-02-06","resultsPosted":"2020-02-17","lastUpdate":"2025-07-18"},"enrollment":882,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Recurrent Head and Neck Cancer","Metastatic Head and Neck Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["KEYTRUDA®","MK-3475"]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"5-FU","otherNames":[]},{"type":"BIOLOGICAL","name":"Cetuximab","otherNames":[]}],"arms":[{"label":"Pembrolizumab Monotherapy (Pembro Mono)","type":"EXPERIMENTAL"},{"label":"Pembrolizumab + Chemotherapy (Pembro Combo)","type":"EXPERIMENTAL"},{"label":"Cetuximab + Chemotherapy (Control)","type":"ACTIVE_COMPARATOR"}],"summary":"Participants with recurrent or metastatic (R/M) squamous cell cancer of the head and neck (HNSCC) will be randomly assigned to receive pembrolizumab monotherapy \\[pembro mono\\], pembrolizumab plus chemotherapy with a platinum-based drug (cisplatin or carboplatin) and 5-Fluorouracil (5-FU) \\[pembro combo\\], or cetuximab plus a platinum-based drug (cisplatin or carboplatin) and 5-FU \\[control\\]. The overall primary study hypotheses are as follows in all participants and in participants with Programmed Cell Death Ligand 1 (PD-L1) positive expression defined by Combined Positive Score (CPS) ≥1 and CPS ≥20: 1) pembrolizumab monotherapy prolongs progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) assessed by Blinded Independent Central Review (BICR) and prolongs overall survival (OS) compared to standard treatment, and 2) pembrolizumab combination with chemotherapy prolongs PFS per RECIST 1.1 assessed by BICR and prolongs OS compared to standard treatment.","primaryOutcome":{"measure":"Pembro Combo vs Control: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in All Participants","timeFrame":"Up to approximately 47 months","effectByArm":[{"arm":"Pembrolizumab + Chemotherapy (Pembro Combo)","deltaMin":4.9,"sd":null},{"arm":"Cetuximab + Chemotherapy (Control)","deltaMin":5.2,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"0.21211"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":18},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["40262400","39382718","37699333","36264378","36219809","35381576","35333599","31679945"],"seeAlso":["https://www.merckclinicaltrials.com","https://msd.trialsummaries.com/Study/StudyDetails?id=26083&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":123,"n":300},"commonTop":["Anaemia","Nausea","Fatigue","Constipation","Diarrhoea"]}}